Clinical Trial: A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

U.S., Dec. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07271667) titled 'A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies' on Nov. 26.

Brief Summary: The primary objective of the study for Cohort 1 and Cohort 2 is to assess the anticancer activity of emavusertib in combination with zanubrutinib in participants with CLL.

Study Start Date: Dec., 2025

Study Type: INTERVENTIONAL

Condition: Chronic Lymphocytic Leukemia B-cell Malignancies

Intervention: DRUG: Emavusertib

Oral tablets

DRUG: Zanubrutinib

Oral capsules

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Curis, Inc.

Published b...